Conformis Inc CFMS
We take great care to ensure that the data presented and summarized in this overview for Conformis Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CFMS
Top Purchases
Top Sells
About CFMS
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
Insider Transactions at CFMS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 05
2023
|
Kenneth P Fallon Iii |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,320
-100.0%
|
-
|
Sep 05
2023
|
Philip W Johnston |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,273
-100.0%
|
-
|
Sep 05
2023
|
Bradley Langdale |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,379
-100.0%
|
-
|
Sep 05
2023
|
Denise E Pedulla FORMER CLO & SECRETARY |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,000
-100.0%
|
-
|
Sep 05
2023
|
Carrie Bienkowski |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,909
-100.0%
|
-
|
Sep 05
2023
|
Gary P Fishetti |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,470
-100.0%
|
-
|
Sep 05
2023
|
Mark A Augusti FORMER PRESIDENT & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
190,277
-100.0%
|
-
|
Sep 05
2023
|
Mark A Augusti FORMER PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
17,778
+8.54%
|
-
|
Sep 05
2023
|
Christine Desrochers Fmr Interim CFO & Controller |
SELL
Sale (or disposition) back to the issuer
|
Direct |
81,465
-100.0%
|
-
|
Apr 25
2023
|
Robert S Howe CFO & TREASURER |
BUY
Grant, award, or other acquisition
|
Direct |
75,150
+8.62%
|
-
|
Apr 25
2023
|
Mark A Augusti FORMER PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
75,150
+2.91%
|
-
|
May 24
2022
|
Carrie Bienkowski |
BUY
Grant, award, or other acquisition
|
Direct |
130,870
+20.82%
|
-
|
May 24
2022
|
Gary P Fishetti |
BUY
Grant, award, or other acquisition
|
Direct |
261,740
+50.0%
|
-
|
May 24
2022
|
Kenneth P Fallon Iii |
BUY
Grant, award, or other acquisition
|
Direct |
130,870
+20.48%
|
-
|
May 24
2022
|
Robert S Howe CFO & TREASURER |
BUY
Grant, award, or other acquisition
|
Direct |
304,615
+29.7%
|
-
|
May 24
2022
|
Philip W Johnston |
BUY
Grant, award, or other acquisition
|
Direct |
130,870
+21.36%
|
-
|
May 24
2022
|
Bradley Langdale |
BUY
Grant, award, or other acquisition
|
Direct |
130,870
+22.17%
|
-
|
May 24
2022
|
Michael D. Milligan Director |
BUY
Grant, award, or other acquisition
|
Direct |
130,870
+34.08%
|
-
|
May 07
2022
|
Mark A Augusti FORMER PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
22,396
-0.91%
|
$0
$0.46 P/Share
|
Mar 14
2022
|
Denise E Pedulla FORMER CLO & SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
450,000
+50.0%
|
-
|